Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiespectus vs Aflibercept in Neovascular Age-related Macular Degeneration
NCT07440225Phase 3Recruiting
- Sponsor
- EyeBio
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of tiespectus in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by EyeBio. Primary endpoint: Mean Change in Best-Corrected Visual Acuity at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
tiespectus
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07440225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07440225.